

# FIRST LOOK ASSAY

Compare multiple  
sample paths



# SLIDING SCORES SLIDING SCORES



Advance the best  
path for discovery

PRESENTED BY



**single cell**  
TECHNOLOGY

AND CASE STUDY CINEMAS




## The Problem

Antibody discovery programs often begin with multiple possible paths, including different species, tissue sources, immunization strategies, animal strains, or enrichment approaches. Limited time, budget, and sample availability make it impractical to fully screen every option, so teams need an early way to compare samples at the single-cell level and identify the one most likely to deliver the right antibodies before committing to full discovery.


## The Solution

First Look Assay is a low-cost, small-scale antibody screening study performed on an aliquot of frozen cells before a full campaign. Using AbTheneum cell isolation and antibody screening, multiple samples are run in parallel under the intended screening plan (Fig. 1).

Because antibodies are not sequenced in First Look, the study remains cost-effective while still delivering meaningful information about each sample's single-cell response. The final report summarizes hit rate, assay performance, and projected hit count to help teams select the best sample and de-risk downstream discovery.



**Figure 1.** First Look Assay workflow for parallel comparison of multiple sample inputs. Samples proceed to cell isolation, antibody screening, and readout to compare single cell activity by sample and identify the strongest sample.



**Figure 2.** Sample A showed stronger performance than Sample B across key screening metrics, supporting full-discovery follow-up of Sample A.

The report summarizes:

- single-cell hit rate
- screening profile under the assay plan
- comparative performance across samples
- projected hit count for a full-scale campaign

First Look helps antibody developers make better early-stage campaign decisions. As shown in Fig. 2, Sample A outperformed Sample B across key screening metrics, identifying the strongest path forward and providing data to support full-scale discovery with greater confidence.



**Learn more at**

[singlecelltechnology.com](https://singlecelltechnology.com)

© 2026